Starbucks heads into the week with its post-earnings rally running out of momentum — and options traders now the most defensively positioned they have been all year.
The options market is flashing the clearest warning signal in this setup. The put/call ratio jumped to 0.94 on May 12, its highest reading in the past 52 weeks and well above its 20-day average of 0.84. That z-score of 2.74 — nearly three standard deviations from the mean — reflects a sharp surge in demand for downside protection. The stock is up 1.6% on the week and 10.3% over the past month to $106.58, so this isn't distress buying; it looks more like traders hedging a stock that has moved a long way in a short time.
Short interest tells a more constructive story. Bears have been covering steadily since the April 28 earnings print. SI as a percentage of free float has fallen from a recent peak of around 3.97% at end of April to 3.51% now — a 10% drop in estimated shares short over the week. Borrow costs are negligible at 0.39%, and borrow availability is wide open. None of that points to meaningful squeeze pressure or aggressive fresh short conviction. The ORTEX short score has drifted lower all week, from 42.4 on May 1 to 40.4 today, consistent with a picture of shorts quietly reducing exposure rather than piling in.
The Street responded to the Q2 beat with a wall of upward target revisions, though the consensus remains split. Bulls at Stifel, Baird, Evercore, and Wells Fargo all raised targets into the $115–$117 range after April 29, keeping Buy or Outperform ratings intact. The neutral camp — UBS, Citigroup, RBC, Guggenheim, and DA Davidson — also raised targets, mostly to the $97–$110 area, but held their cautious ratings. BNP Paribas, the lone bear, lifted its Underperform target to $87. The mean consensus price target runs at $105.62, just below Tuesday's close of $106.58, which means the stock is now trading through the average Street target — a level that historically tightens headroom for further re-rating without a material upgrade cycle. The EV/EBITDA multiple at 24.2x has compressed roughly 4% over the past month, a small but notable move in the right direction for value-conscious holders. The P/E remains elevated at 40.8x. EPS momentum factor scores are strong — ranked in the 87th and 80th percentiles on 30- and 90-day windows — which at least supports the view that estimate revisions are running in the right direction.
The institutional picture is orderly. Capital Research holds 16.2% of shares outstanding, easily the largest bloc, and added nearly 5 million shares as recently as April. Vanguard and BlackRock both added modestly in the same period. T. Rowe Price's position increased by nearly 8 million shares in the quarter to March. None of the major holders are showing meaningful rotation out. Insider activity over the past 90 days has been all sells — a division CEO, an EVP, and the CFO all liquidated small positions in the $90–$105 range — but transaction values are in the low hundreds of thousands. Significance scores are uniformly low (1–2 out of 10). This reads as routine post-vesting disposal rather than any signal on the fundamental outlook.
The Q2 earnings report itself was the dominant catalyst: the stock surged 7.8% the day after the April 28 release and held those gains into the following week (+7.2% over five days). CEO Brian Niccol's turnaround narrative is clearly gaining traction with investors, and the bull case centres on accelerating same-store sales recovery, loyalty programme momentum, and cost discipline. The bear case focuses on labour cost headwinds, low near-term store growth targets, and the fragility of a recovery still in early innings. With the next earnings event not until July 28, what matters most in the near term is whether the Street's neutral majority upgrades its ratings — or keeps the stock range-bound at a consensus target it has now effectively priced through.
See the live data behind this article on ORTEX.
Open SBUX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
